Sotorasib in KRAS p.G12C-mutated Pancreatic Cancer

The FDA granted accelerated approval to zenocutuzumab for adults with NRG1-positive NSCLC or pancreatic adenocarcinoma.

Is ctDNA ready for prime time in solid tumors? Two studies presented at ASCO 2024 highlight the biomarkers’ potential in colon and pancreatic cancers.

The FDA approved lutetium Lu 177 dotatate (Lutathera) in children aged 12 years and older with SSTR-positive gastroenteropancreatic neuroendocrine tumors.

Patients who responded to an investigational mRNA vaccine continue to show strong T-cell responses, and many remain recurrence-free at three years.

The FDA updated safety labeling for fluorouracil injection products. The changes pertain to patients with dihydropyrimidine dehydrogenase deficiency.

The FDA approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin as a first-line treatment in metastatic pancreatic adenocarcinoma.

Results of the NETTER-2 trial provide “a new, safe treatment option in a field with no established standard of care,” a study author said.

Anticipated presentations at ASCO GI 2024 include insights into early-onset cancer, the use of AI to process biomarker data, and ways to speed up FDA approvals.

Progress has been painfully slow in pancreatic cancer care. However, recent studies suggest that more effective treatments may be coming.

Results from an international randomized trial show minimally invasive distal pancreatectomy is comparable to an open approach in terms of safety and efficacy.

mRNA vaccination has shown recent efficacy in melanoma. Bob Figlin, MD, and Jeffrey Weber, MD, PhD, discuss FDA approval and other cancers that may benefit.